RayzeBio, Inc.
Clinical trials sponsored by RayzeBio, Inc., explained in plain language.
Biotech developing radiopharmaceutical therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New scan could reveal hidden kidney cancer Results expected Dec 2026 (estimated)
- New radioactive drug aims to fight gut tumors that resist standard therapy Results expected Dec 2026 (estimated)
- Radioactive drug takes aim at Hard-to-Treat tumors Results expected Feb 2027 (estimated)
- New imaging tracer could spot hidden cancers Results expected Jul 2027 (estimated)
- New combo therapy targets tough lung cancer in early trial Results expected Jul 2027 (estimated)
-
New radiation drug shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …
Phase 1/2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests a new drug called RYZ101 added to standard chemotherapy and immunotherapy for people with a specific type of advanced small cell lung cancer that has spread. The main goals are to check safety and find the best dose. About 21 adults who have not had t…
Phase 1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC